 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Qtrypta (zolmitriptan-coated microneedle patch) / Zosano, zolmitriptan intracutaneous microneedle system (C213) / Zosano
Journal: Development of a novel zolmitriptan intracutaneous microneedle system (Qtrypta™) for the acute treatment of migraine. (Pubmed Central) - Oct 30, 2021
Treatment-emergent adverse events were mild and transient and most commonly concerned the application site. In post hoc analyses: pain freedom was sustained in approximately 1/3 of patients; efficacy was observed in migraine headaches that are typically more difficult to treat.
- | zolmitriptan intracutaneous microneedle system (C213) / Zosano
Journal: Differentially Amplified Repetitive Sequences Among Aegilops tauschii Subspecies and Genotypes. (Pubmed Central) - Sep 8, 2021
However, two Ty3/gypsy retrotransposons (CL62 and CL87) showed significantly higher abundances, and CL1, CL119, CL213, CL217 tandem repeats, and CL142 retrotransposon (Ty1/copia type) showed significantly lower abundances in subspecies strangulata compared with the subspecies anathera and meyeri...Taken together, the different classes of repetitive DNA sequences have differentially accumulated between strangulata and the other two subspecies of Ae. tauschii that is generally in agreement with spike morphology, implying that factors affecting repeatome evolution are variable even among highly closely related lineages.
- || zolmitriptan intracutaneous microneedle system (C213) / Zosano
Trial completion, Trial completion date, Trial primary completion date: Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches (clinicaltrials.gov) - Jul 21, 2021
P2/3, N=42, Completed, Sponsor: Zosano Pharma Corporation
tauschii that is generally in agreement with spike morphology, implying that factors affecting repeatome evolution are variable even among highly closely related lineages. Active, not recruiting --> Completed | Trial completion date: Jul 2021 --> Apr 2021 | Trial primary completion date: Jul 2021 --> Apr 2021
- || Bexsero (meningococcal group B vaccine) / GSK
Clinical, Journal: Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands. (Pubmed Central) - Apr 28, 2021
Since the coverage of the 4CMenB vaccine is dependent on circulating clonal complexes, our findings emphasize the need for surveillance of circulating meningococcal strains. In addition, estimation of age specific coverage is relevant to determine the right target age group for vaccination.
- | Trumenba (meningococcal B vaccine) / Pfizer, zolmitriptan intracutaneous microneedle system (C213) / Zosano, Bexsero (meningococcal group B vaccine) / GSK
Journal: Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: evolution of the vaccine antigen factor H binding protein (FHbp). (Pubmed Central) - Apr 24, 2021
In addition, estimation of age specific coverage is relevant to determine the right target age group for vaccination. Due to invasive meningococcal strains temporal variability (eg prevalence of the cc213 increased from 3.6% in 2007 to 33% in 2018) affecting to the presence and distribution of the vaccine antigens, continuous detailed meningococcal surveillance and monitoring of the vaccine antigens is needed to determine the degree and durability of coverage provided by these protein vaccine.
- zolmitriptan intracutaneous microneedle system (C213) / Zosano
[VIRTUAL] Frequency and spectrum of mutations in the BRCA1, BRCA2, PALB2, P53, PTEN, CHEK2, CDH1 genes in women from 3 cities of Colombia () - Mar 2, 2021 - Abstract #SGBCC2021SG_BCC_287;
one variant of uncertain significance showed pathogenic evidence in silico (CHEK2: C.497A>G) and it was found in three cases. Conclusion(s): This is the first study in Colombia that evaluates genes different from BRCA1 and BRCA2 in unselected cases in Colombia, and the frequency of pathogenic mutations was 4.4%.
- | zolmitriptan intracutaneous microneedle system (C213) / Zosano
Journal: Genomic surveillance of Neisseria meningitidis serogroup B invasive strains: Diversity of vaccine antigen types, Brazil, 2016-2018. (Pubmed Central) - Jan 26, 2021
Conclusion(s): This is the first study in Colombia that evaluates genes different from BRCA1 and BRCA2 in unselected cases in Colombia, and the frequency of pathogenic mutations was 4.4%. During the study period, changes in the clonal structure of circulating strains were observed, without a predominance of a single hyperinvasive lineage, indicating that an epidemiologic shift has occurred that led to a diversity of vaccine antigen types in recent years in Brazil.
- | zolmitriptan intracutaneous microneedle system (C213) / Zosano
Journal: Meningococcal B vaccine antigen FHbp variants among disease-causing Neisseria meningitidis B isolates, Italy, 2014-2017. (Pubmed Central) - Jan 23, 2021
A dynamic trend in clonal complexes distribution within MenB was detected. Our results stress the importance of continued meningococcal molecular surveillance to evaluate the potential vaccine coverage of the available MenB vaccines.
- ||||| zolmitriptan intracutaneous microneedle system (C213) / Zosano
Enrollment closed, Enrollment change: Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches (clinicaltrials.gov) - Jan 13, 2021
P2/3, N=41, Active, not recruiting, Sponsor: Zosano Pharma Corporation
Our results stress the importance of continued meningococcal molecular surveillance to evaluate the potential vaccine coverage of the available MenB vaccines. Recruiting --> Active, not recruiting | N=120 --> 41
- ||||| zolmitriptan intracutaneous microneedle system (C213) / Zosano
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches (clinicaltrials.gov) - Jun 23, 2020
P2/3, N=120, Recruiting, Sponsor: Zosano Pharma Corporation
Recruiting --> Active, not recruiting | N=120 --> 41 Active, not recruiting --> Recruiting | N=20 --> 120 | Trial completion date: Apr 2021 --> Jul 2021 | Trial primary completion date: Apr 2021 --> Jul 2021
- ||||| zolmitriptan intracutaneous microneedle system (C213) / Zosano
Enrollment closed, Enrollment change: Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches (clinicaltrials.gov) - Mar 31, 2020
P2/3, N=20, Active, not recruiting, Sponsor: Zosano Pharma Corporation
Active, not recruiting --> Recruiting | N=20 --> 120 | Trial completion date: Apr 2021 --> Jul 2021 | Trial primary completion date: Apr 2021 --> Jul 2021 Recruiting --> Active, not recruiting | N=120 --> 20
- | zolmitriptan intracutaneous microneedle system (C213) / Zosano
Enrollment open: Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches (clinicaltrials.gov) - Oct 17, 2019
P2/3, N=120, Recruiting, Sponsor: Zosano Pharma Corporation
Recruiting --> Active, not recruiting | N=120 --> 20 Not yet recruiting --> Recruiting
- | zolmitriptan intracutaneous microneedle system (C213) / Zosano
New P2/3 trial: Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches (clinicaltrials.gov) - Aug 22, 2019
P2/3, N=120, Not yet recruiting, Sponsor: Zosano Pharma Corporation
- ||||||| zolmitriptan intracutaneous microneedle system (C213) / Zosano
Trial completion: ADAM: A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine (clinicaltrials.gov) - May 21, 2019
P3, N=344, Completed, Sponsor: Zosano Pharma Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | zolmitriptan intracutaneous microneedle system (C213) / Zosano
Enrollment change: ADAM: A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine (clinicaltrials.gov) - Nov 5, 2018
P3, N=344, Active, not recruiting, Sponsor: Zosano Pharma Corporation
Active, not recruiting --> Completed N=250 --> 344
- | zolmitriptan intracutaneous microneedle system (C213) / Zosano
Enrollment closed: ADAM: A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine (clinicaltrials.gov) - Jun 6, 2018
P3, N=250, Active, not recruiting, Sponsor: Zosano Pharma Corporation
N=250 --> 344 Recruiting --> Active, not recruiting
- | zolmitriptan intracutaneous microneedle system (C213) / Zosano
Enrollment open: ADAM: A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine (clinicaltrials.gov) - Nov 13, 2017
P3, N=250, Recruiting, Sponsor: Zosano Pharma Corporation
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | zolmitriptan intracutaneous microneedle system (C213) / Zosano
New P3 trial: ADAM: A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine (clinicaltrials.gov) - Sep 13, 2017
P3, N=250, Not yet recruiting, Sponsor: Zosano Pharma Corporation
- ||||||| zolmitriptan intracutaneous microneedle system (C213) / Zosano
Trial completion: Zotrip: Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine (clinicaltrials.gov) - Aug 11, 2017
P2/3, N=365, Completed, Sponsor: Zosano Pharma Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| zolmitriptan intracutaneous microneedle system (C213) / Zosano
Enrollment closed: Zotrip: Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine (clinicaltrials.gov) - Jan 10, 2017
P2/3, N=365, Active, not recruiting, Sponsor: Zosano Pharma Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||| zolmitriptan intracutaneous microneedle system (C213) / Zosano
Enrollment open: Zotrip: Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine (clinicaltrials.gov) - Jun 22, 2016
P2/3, N=360, Recruiting, Sponsor: Zosano Pharma Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| zolmitriptan intracutaneous microneedle system (C213) / Zosano
New P2/3 trial: Zotrip: Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine (clinicaltrials.gov) - Apr 20, 2016
P2/3, N=360, Not yet recruiting, Sponsor: Zosano Pharma Inc.